Breast Cancer | Hope S Rugo, MD

Dr Rugo on Elacestrant-Based Combinations in ER+/HER2– Metastatic Breast CancerПодробнее

WATCH NOW: Transforming Metastatic Breast Cancer Management: Harnessing the Power of…Подробнее

Identification & Treatment of Patients w/ HR+, HER2- #EarlyBreastCancer at a High Risk of RecurrenceПодробнее

UCSF Bay Area Breast Cancer Forum: "Updates from ASCO 2024”Подробнее

ER-Positive Metastatic Breast Cancer | Third Annual National General Medical Oncology SummitПодробнее

UCSF Bay Area Breast Cancer Forum: "Updates from San Antonio Breast Cancer Symposium 2023"Подробнее

Addressing Current Questions and Controversies in the Management of Metastatic Breast CancerПодробнее

Optimizing Early Breast Cancer Outcomes in the Community Setting: An Expert Review of Emerging Th...Подробнее

Poster Pearl: Treating ER+/HER2- mBC with Elacestrant and Endocrine TherapyПодробнее

Dr Rugo on Managing Treatment-Limiting Toxicities in Breast CancerПодробнее

UCSF at #AACR24: Hope Rugo, MD | Clinical Trials Discussant on "Advanced in Targeted Therapy"Подробнее

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast C...Подробнее

DESTINY-Breast04 and Other Key Breast Cancer Studies at ASCO22Подробнее

Dr. Hope Rugo discusses Capivasertib FDA Approval based on CAPItello-291 StudyПодробнее

Metastatic HER2-Positive and Triple-Negative BC | Annual National General Medical Oncology SummitПодробнее

7 Dr Hope RugoПодробнее

SABCS Clinical Case DiscussionsПодробнее

Exploring Efficacy & Overall Survival in the TROPiCS-02 TrialПодробнее

Inside the Issue: Optimizing the Management of Metastatic BRCA-Negative, Triple-Negative Breast C...Подробнее